Logo image of CLBS

CALADRIUS BIOSCIENCES INC (CLBS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CLBS - US1280582032 - Common Stock

0.4264 USD
-0.08 (-16.44%)
Last: 9/14/2022, 8:18:27 PM
0.421 USD
-0.01 (-1.27%)
After Hours: 9/14/2022, 8:18:27 PM
Fundamental Rating

2

Overall CLBS gets a fundamental rating of 2 out of 10. We evaluated CLBS against 529 industry peers in the Biotechnology industry. While CLBS seems to be doing ok healthwise, there are quite some concerns on its profitability. CLBS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CLBS has reported negative net income.
CLBS Yearly Net Income VS EBIT VS OCF VS FCFCLBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -28.61%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLBS Yearly ROA, ROE, ROICCLBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -200 -400 -600

1.3 Margins

CLBS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLBS Yearly Profit, Operating, Gross MarginsCLBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

CLBS has more shares outstanding than it did 1 year ago.
There is no outstanding debt for CLBS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLBS Yearly Shares OutstandingCLBS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 1M 2M 3M 4M 5M
CLBS Yearly Total Debt VS Total AssetsCLBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

CLBS has an Altman-Z score of -7.31. This is a bad value and indicates that CLBS is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for CLBS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.31
ROIC/WACCN/A
WACCN/A
CLBS Yearly LT Debt VS Equity VS FCFCLBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 22.33 indicates that CLBS has no problem at all paying its short term obligations.
A Quick Ratio of 22.33 indicates that CLBS has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 22.33
Quick Ratio 22.33
CLBS Yearly Current Assets VS Current LiabilitesCLBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.33% over the past year.
EPS 1Y (TTM)52.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CLBS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.95% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.62%
EPS Next 2Y13.75%
EPS Next 3Y10.59%
EPS Next 5Y3.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLBS Yearly Revenue VS EstimatesCLBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2023 2024 2025 2026 10M 20M 30M
CLBS Yearly EPS VS EstimatesCLBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLBS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLBS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLBS Price Earnings VS Forward Price EarningsCLBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.63
CLBS Per share dataCLBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.75%
EPS Next 3Y10.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLBS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CALADRIUS BIOSCIENCES INC

NASDAQ:CLBS (9/14/2022, 8:18:27 PM)

After market: 0.421 -0.01 (-1.27%)

0.4264

-0.08 (-16.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2022-08-04/amc
Earnings (Next)11-02 2022-11-02
Inst Owners0.02%
Inst Owner Change0%
Ins Owners101.58%
Ins Owner Change0%
Market Cap1.72M
Revenue(TTM)N/A
Net Income(TTM)-24.57M
Analysts82.5
Price Target4.59 (976.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.02
P/tB N/A
EV/EBITDA 2.63
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS20.4
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.61%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.33
Quick Ratio 22.33
Altman-Z -7.31
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
EPS Next Y17.62%
EPS Next 2Y13.75%
EPS Next 3Y10.59%
EPS Next 5Y3.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

CALADRIUS BIOSCIENCES INC / CLBS FAQ

Can you provide the ChartMill fundamental rating for CALADRIUS BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to CLBS.


What is the valuation status for CLBS stock?

ChartMill assigns a valuation rating of 2 / 10 to CALADRIUS BIOSCIENCES INC (CLBS). This can be considered as Overvalued.


Can you provide the profitability details for CALADRIUS BIOSCIENCES INC?

CALADRIUS BIOSCIENCES INC (CLBS) has a profitability rating of 2 / 10.


What is the earnings growth outlook for CALADRIUS BIOSCIENCES INC?

The Earnings per Share (EPS) of CALADRIUS BIOSCIENCES INC (CLBS) is expected to grow by 17.62% in the next year.


Is the dividend of CALADRIUS BIOSCIENCES INC sustainable?

The dividend rating of CALADRIUS BIOSCIENCES INC (CLBS) is 0 / 10 and the dividend payout ratio is 0%.